Aviscumine

Drug Profile

Aviscumine

Alternative Names: BA503; CY-503; ME-503; Mistletoe lectin recombinant; Recombinant mistletoe lectin; Recombinant viscumin; Recombinant viscumine; rViscumin; Viscum ribosome inactivating protein

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VISCUM AG
  • Developer MELEMA Pharma GmbH
  • Class Antineoplastics; Biological toxins; Lectins; Plant proteins
  • Mechanism of Action 28S ribosomal RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Malignant melanoma

Most Recent Events

  • 16 Apr 2016 Phase II development for aviscumine is ongoing in Germany and Autria
  • 16 Apr 2016 Final Efficacy data from a phase II trial in Melanoma presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR -2016)
  • 31 Aug 2012 Cytavis Biopharma terminates a phase II trial in Colorectal cancer (metastatic disease, second-line or greater therapy) in Germany and Austria due to poor recruitment (NCT00932724)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top